Interní Med. 2015; 17(5): 252-255

Empagliflozin in clinical practice: Better news, at last

MUDr.Barbora Doležalová1,2
1 Univerzita Pardubice, Fakulta zdravotnických studií, Katedra klinických oborů
2 IDE CR s. r. o., Chrudim

The case study presents the experience with empagliflozin therapy as add-on to insulin and metformin in a poorly controlled type 2

diabetes patient. 7 months of treatment led to HbA1c decrease of 15 mmol/mol, together with a weight loss of 3 kg. The treatment was

well tolerated, and despite the combination with insulin, hypoglycaemia did not occur. Next therapeutic efforts must be made to sustain

the improvement, or eventually, to further improve HbA1c level in order to prevent long-term complications of diabetes.

Keywords: empagliflozin, case study, type 2 diabetes, weight loss

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová B. Empagliflozin in clinical practice: Better news, at last. Interní Med. 2015;17(5):252-255.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Inzucchi SE, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient - Centered Approach. Diabetes Care 2015; 38: 140-149. DOI: 10.2337/dc14-2441. Go to original source... Go to PubMed...
    2. de Pablos-Velasco P. et al. Data From the PANORAMA Study. Clin Endocrinol. 2014; 80(1): 47-56. Go to original source... Go to PubMed...
    3. Garber A, et al. AACE/ACE Comprehensive Diabetes Management Algorithm 2015. Endocr Pract 2015; 21: 438-447. Go to original source... Go to PubMed...
    4. Škrha J. Empagliflozin a současné postavení inhibitorů SGLT2 v terapii diabetu 2. typu. Farmakoterapie 2015; 11(1): 98-103.
    5. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009; 58(4): 773-795. DOI: 10.2337/db09-9028. Go to original source... Go to PubMed...
    6. Rosenstock J, et al. Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism 2015; 17: 936-948. DOI: 10.1111/dom.12503. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.